FOXP3 and neoplasm: Moreover, in a preclinical in vivo model of SCLC, the tumor impairment observed with the combined use of PARPi and anti-PD-L1 was accompanied by reduced CD4+FOXP3 Treg frequency and amplified cytotoxic CD8+ T cell response [96].